Targeting Neuroinflammation as Disease Modifying Approach to Alzheimer’s Disease: Potential and Challenges

Jain, S.; Bisht, A.; Verma, K.; Negi, S.; Paliwal, S.; Sharma, S. The role of fatty acid amide hydrolase enzyme inhibitors in Alzheimer’s Disease. Cell Biochem. Funct., 2021, 40, 106-117.
[http://dx.doi.org/10.1002/cbf.3680] [PMID: 34931308]

Rubio-Perez, J.M.; Morillas-Ruiz, J.M. A review: Inflammatory process in Alzheimer’s disease, role of cytokines. Sci. World J., 2012, 2012, 1-15.
[http://dx.doi.org/10.1100/2012/756357] [PMID: 22566778]

Askin, S.; Tahtaci, H. Türkeş C.; Demir, Y.; Ece, A.; Akalın Çiftçi, G.; Beydemir, Ş. Design, synthesis, characterization, in vitro and in silico evaluation of novel imidazo[2,1-b][1,3,4]thiadiazoles as highly potent acetylcholinesterase and non-classical carbonic anhydrase inhibitors. Bioorg. Chem., 2021, 113, 105009.
[http://dx.doi.org/10.1016/j.bioorg.2021.105009] [PMID: 34052739]

Knopman, D.S.; Amieva, H.; Petersen, R.C.; Chételat, G.; Holtzman, D.M.; Hyman, B.T.; Nixon, R.A.; Jones, D.T. Alzheimer Disease. Nat. Rev. Dis. Primers, 2021, 7(1), 1-21.
[http://dx.doi.org/10.1038/s41572-021-00269-y]

Alzheimer’s Disease. Facts Fig; Alzheimer’s Association, 2022.

Türkan, F.; Huyut, Z.; Demir, Y. Ertaş F.; Beydemir, Ş. The effects of some cephalosporins on acetylcholinesterase and glutathione S-transferase: an in vivo and in vitro study. Arch. Physiol. Biochem., 2019, 125(3), 235-243.
[http://dx.doi.org/10.1080/13813455.2018.1452037] [PMID: 29564935]

Gümüş M.; Babacan, Ş.N.; Demir, Y.; Sert, Y.; Koca, İ.; Gülçin, İ. Discovery of sulfadrug–pyrrole conjugates as carbonic anhydrase and acetylcholinesterase inhibitors. Arch. Pharm., 2022, 355(1), 2100242.
[http://dx.doi.org/10.1002/ardp.202100242] [PMID: 34609760]

Calsolaro, V.; Edison, P. Neuroinflammation in Alzheimer’s disease: Current evidence and future directions. Alzheimers Dement., 2016, 12(6), 719-732.
[http://dx.doi.org/10.1016/j.jalz.2016.02.010] [PMID: 27179961]

Szabo, L.; Eckert, A.; Grimm, A. Insights into disease-associated tau impact on mitochondria. Int. J. Mol. Sci., 2020, 21(17), 6344.
[http://dx.doi.org/10.3390/ijms21176344] [PMID: 32882957]

Vogel, J.W.; Iturria-Medina, Y.; Strandberg, O.T.; Smith, R.; Levitis, E.; Evans, A.C.; Hansson, O.; Weiner, M.; Aisen, P.; Petersen, R.; Jack, C.R., Jr; Jagust, W.; Trojanowki, J.Q.; Toga, A.W.; Beckett, L.; Green, R.C.; Saykin, A.J.; Morris, J.; Shaw, L.M.; Liu, E.; Montine, T.; Thomas, R.G.; Donohue, M.; Walter, S.; Gessert, D.; Sather, T.; Jiminez, G.; Harvey, D.; Donohue, M.; Bernstein, M.; Fox, N.; Thompson, P.; Schuff, N. DeCArli, C.; Borowski, B.; Gunter, J.; Senjem, M.; Vemuri, P.; Jones, D.; Kantarci, K.; Ward, C.; Koeppe, R.A.; Foster, N.; Reiman, E.M.; Chen, K.; Mathis, C.; Landau, S.; Cairns, N.J.; Householder, E.; Reinwald, L.T.; Lee, V.; Korecka, M.; Figurski, M.; Crawford, K.; Neu, S.; Foroud, T.M.; Potkin, S.; Shen, L.; Kelley, F.; Kim, S.; Nho, K.; Kachaturian, Z.; Frank, R.; Snyder, P.J.; Molchan, S.; Kaye, J.; Quinn, J.; Lind, B.; Carter, R.; Dolen, S.; Schneider, L.S.; Pawluczyk, S.; Beccera, M.; Teodoro, L.; Spann, B.M.; Brewer, J.; Vanderswag, H.; Fleisher, A.; Heidebrink, J.L.; Lord, J.L.; Petersen, R.; Mason, S.S.; Albers, C.S.; Knopman, D.; Johnson, K.; Doody, R.S.; Meyer, J.V.; Chowdhury, M.; Rountree, S.; Dang, M.; Stern, Y.; Honig, L.S.; Bell, K.L.; Ances, B.; Morris, J.C.; Carroll, M.; Leon, S.; Householder, E.; Mintun, M.A.; Schneider, S.; OliverNG, A.; Griffith, R.; Clark, D.; Geldmacher, D.; Brockington, J.; Roberson, E.; Grossman, H.; Mitsis, E.; de Toledo-Morrell, L.; Shah, R.C.; Duara, R.; Varon, D.; Greig, M.T.; Roberts, P.; Albert, M.; Onyike, C.; D’Agostino, D., II; Kielb, S.; Galvin, J.E.; Pogorelec, D.M.; Cerbone, B.; Michel, C.A.; Rusinek, H.; de Leon, M.J.; Glodzik, L.; De Santi, S.; Doraiswamy, P.M.; Petrella, J.R.; Wong, T.Z.; Arnold, S.E.; Karlawish, J.H.; Wolk, D.; Smith, C.D.; Jicha, G.; Hardy, P.; Sinha, P.; Oates, E.; Conrad, G.; Lopez, O.L.; Oakley, M.A.; Simpson, D.M.; Porsteinsson, A.P.; Goldstein, B.S.; Martin, K.; Makino, K.M.; Ismail, M.S.; Brand, C.; Mulnard, R.A.; Thai, G.; Mc Adams Ortiz, C.; Womack, K.; Mathews, D.; Quiceno, M.; Arrastia, R.D.; King, R.; Weiner, M.; Cook, K.M.; DeVous, M.; Levey, A.I.; Lah, J.J.; Cellar, J.S.; Burns, J.M.; Anderson, H.S.; Swerdlow, R.H.; Apostolova, L.; Tingus, K.; Woo, E.; Silverman, D.H.S.; Lu, P.H.; Bartzokis, G.; Radford, N.R.G.; Parfitt, F.; Kendall, T.; Johnson, H.; Farlow, M.R.; Hake, A.M.; Matthews, B.R.; Herring, S.; Hunt, C.; van Dyck, C.H.; Carson, R.E.; MacAvoy, M.G.; Chertkow, H.; Bergman, H.; Hosein, C.; Black, S.; Stefanovic, B.; Caldwell, C.; Hsiung, G.Y.R.; Feldman, H.; Mudge, B.; Past, M.A.; Kertesz, A.; Rogers, J.; Trost, D.; Bernick, C.; Munic, D.; Kerwin, D.; Mesulam, M.M.; Lipowski, K.; Wu, C.K.; Johnson, N.; Sadowsky, C.; Martinez, W.; Villena, T.; Turner, R.S.; Johnson, K.; Reynolds, B.; Sperling, R.A.; Johnson, K.A.; Marshall, G.; Frey, M.; Yesavage, J.; Taylor, J.L.; Lane, B.; Rosen, A.; Tinklenberg, J.; Sabbagh, M.N.; Belden, C.M.; Jacobson, S.A.; Sirrel, S.A.; Kowall, N.; Killiany, R.; Budson, A.E.; Norbash, A.; Johnson, P.L.; Obisesan, T.O.; Wolday, S.; Allard, J.; Lerner, A.; Ogrocki, P.; Hudson, L.; Fletcher, E.; Carmichael, O.; Olichney, J.; DeCarli, C.; Kittur, S.; Borrie, M.; Lee, T.Y.; Bartha, R.; Johnson, S.; Asthana, S.; Carlsson, C.M.; Potkin, S.G.; Preda, A.; Nguyen, D.; Tariot, P.; Fleisher, A.; Reeder, S.; Bates, V.; Capote, H.; Rainka, M.; Scharre, D.W.; Kataki, M.; Adeli, A.; Zimmerman, E.A.; Celmins, D.; Brown, A.D.; Pearlson, G.D.; Blank, K.; Anderson, K.; Santulli, R.B.; Kitzmiller, T.J.; Schwartz, E.S.; SinkS, K.M.; Williamson, J.D.; Garg, P.; Watkins, F.; Ott, B.R.; Querfurth, H.; Tremont, G.; Salloway, S.; Malloy, P.; Correia, S.; Rosen, H.J.; Miller, B.L.; Mintzer, J.; Spicer, K.; Bachman, D.; Finger, E.; Pasternak, S.; Rachinsky, I.; Rogers, J.; Kertesz, A.; Drost, D.; Pomara, N.; Hernando, R.; Sarrael, A.; Schultz, S.K.; Boles Ponto, L.L.; Shim, H.; Smith, K.E.; Relkin, N.; Chaing, G.; Raudin, L.; Smith, A.; Fargher, K.; Raj, B.A.; Andersson, E.; Berron, D.; Byman, E.; Sundberg-Brorsson, T.; Administrator; Borland, E.; Callmer, A.; Dahl, C.; Gertje, E.; Gustavsson, A-M.; Grzegorska, J.; Hall, S.; Hansson, O.; Insel, P.; Janelidze, S.; Johansson, M.; Sletten, H.; Jester-Broms, J.; Londos, E.; Mattson, N.; Minthon, L.; Nilsson, M.; Nordkvist, R.; Nägga, K.; Orbjörn, C.; Ossenkoppele, R.; Palmqvist, S.; Persson, M.; Santillo, A.; Spotorno, N.; Stomrud, E.; Toresson, H.; Strandberg, O.; Schöll, M.; Friberg, I.; Johansson, P.; Wibom, M.; Johansson, K.; Pettersson, E.; Karremo, C.; Smith, R.; Surova, Y.; Jalakas, M.; Lätt, J.; Mannfolk, P.; Nilsson, M.; Ståhlberg, F.; Sundgren, P.; van Westen, D.; Andreasson, U.; Blennow, K.; Zetterberg, H.; Wahlund, L-O.; Westman, E.; Pereira, J.; Jögi, J.; Hägerström, D.; Olsson, T.; Wollmer, P. Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease. Nat. Commun., 2020, 11(1), 2612.
[http://dx.doi.org/10.1038/s41467-020-15701-2] [PMID: 32457389]

Kayed, R.; Lasagna-Reeves, C.A. Molecular mechanisms of amyloid oligomers toxicity. J. Alzheimers Dis., 2012, 33(S1), S67-S78.
[http://dx.doi.org/10.3233/JAD-2012-129001] [PMID: 22531422]

Hassan, M.; Shahzadi, S.; Seo, S.Y.; Alashwal, H.; Zaki, N.; Moustafa, A.A. Molecular docking and dynamic simulation of azd3293 and solanezumab effects against bace1 to treat Alzheimer’s disease. Front. Comput. Neurosci., 2018, 12(6), 34.
[http://dx.doi.org/10.3389/fncom.2018.00034] [PMID: 29910719]

Lee, J.H.; Agacinski, G.; Williams, J.H.; Wilcock, G.K.; Esiri, M.M.; Francis, P.T.; Wong, P.T.H.; Chen, C.P.; Lai, M.K.P. Intact cannabinoid CB1 receptors in the Alzheimer’s disease cortex. Neurochem. Int., 2010, 57(8), 985-989.
[http://dx.doi.org/10.1016/j.neuint.2010.10.010] [PMID: 21034788]

Zhao, Y.; Zhao, B. Review article oxidative stress and the pathogenesis of Alzheimer’s Disease. Oxid. Med. Cell. Longev., 2013, 2013, 316523.
[http://dx.doi.org/10.1155/2013/316523] [PMID: 23983897]

Skaper, S.D. Alzheimer’s Disease and amyloid: Culprit or coincidence? Int. Rev. Neurobiol., 2012, 102, 277-316.
[http://dx.doi.org/10.1016/B978-0-12-386986-9.00011-9]

Tarkowski, E.; Andreasen, N.; Tarkowski, A.; Blennow, K. Intrathecal inflammation precedes development of Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry, 2003, 74(9), 1200-1205.
[http://dx.doi.org/10.1136/jnnp.74.9.1200] [PMID: 12933918]

DaRocha-Souto, B.; Scotton, T.C.; Coma, M.; Serrano-Pozo, A.; Hashimoto, T.; Serenó, L.; Rodríguez, M.; Sánchez, B.; Hyman, B.T.; Gómez-Isla, T. Brain oligomeric β-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein/tau transgenic mice. J. Neuropathol. Exp. Neurol., 2011, 70(5), 360-376.
[http://dx.doi.org/10.1097/NEN.0b013e318217a118] [PMID: 21487307]

Pereira, C.F.; Santos, A.E.; Moreira, P.I.; Pereira, A.C.; Sousa, F.J.; Cardoso, S.M.; Cruz, M.T. Is Alzheimer’s disease an inflammasomopathy? Ageing Res. Rev., 2019, 56(8), 100966.
[http://dx.doi.org/10.1016/j.arr.2019.100966] [PMID: 31577960]

Kothari, V.; Luo, Y.; Tornabene, T.; O’Neill, A.M.; Greene, M.W.; Geetha, T.; Babu, J.R. High fat diet induces brain insulin resistance and cognitive impairment in mice. Biochim. Biophys. Acta Mol. Basis Dis., 2017, 1863(2), 499-508.
[http://dx.doi.org/10.1016/j.bbadis.2016.10.006] [PMID: 27771511]

Wei, L.; Yao, M.; Zhao, Z.; Jiang, H.; Ge, S. High-fat diet aggravates postoperative cognitive dysfunction in aged mice. BMC Anesthesiol., 2018, 18(1), 20.
[http://dx.doi.org/10.1186/s12871-018-0482-z] [PMID: 29439655]

Hermes, D.J.; Yadav-Samudrala, B.J.; Xu, C.; Paniccia, J.E.; Meeker, R.B.; Armstrong, M.L.; Reisdorph, N.; Cravatt, B.F.; Mackie, K.; Lichtman, A.H.; Ignatowska-Jankowska, B.M.; Lysle, D.T.; Fitting, S. GPR18 drives FAAH inhibition-induced neuroprotection against HIV-1 Tat-induced neurodegeneration. Exp. Neurol., 2021, 341(3), 113699.
[http://dx.doi.org/10.1016/j.expneurol.2021.113699] [PMID: 33736974]

Prillaman, M. Alzheimer’s drug slows mental decline in trial — but is it a breakthrough? Nature, 2022, 610(7930), 15-16.
[http://dx.doi.org/10.1038/d41586-022-03081-0] [PMID: 36175566]

Klyucherev, T.O.; Olszewski, P.; Shalimova, A.A.; Chubarev, V.N.; Tarasov, V.V.; Attwood, M.M.; Syvänen, S.; Schiöth, H.B. Advances in the development of new biomarkers for Alzheimer’s disease. Transl. Neurodegener., 2022, 11(1), 25.
[http://dx.doi.org/10.1186/s40035-022-00296-z] [PMID: 35449079]

Wang, Y.Y.; Sun, Y.P.; Luo, Y.M.; Peng, D.H.; Li, X.; Yang, B.Y.; Wang, Q.H.; Kuang, H.X. Biomarkers for the clinical diagnosis of Alzheimer’s Disease: Metabolomics analysis of brain tissue and blood. Front. Pharmacol., 2021, 12, 700587.
[http://dx.doi.org/10.3389/fphar.2021.700587] [PMID: 34366852]

Jack, C.R., Jr; Bennett, D.A.; Blennow, K.; Carrillo, M.C.; Dunn, B.; Haeberlein, S.B.; Holtzman, D.M.; Jagust, W.; Jessen, F.; Karlawish, J.; Liu, E.; Molinuevo, J.L.; Montine, T.; Phelps, C.; Rankin, K.P.; Rowe, C.C.; Scheltens, P.; Siemers, E.; Snyder, H.M.; Sperling, R.; Elliott, C.; Masliah, E.; Ryan, L.; Silverberg, N. NIA‐AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement., 2018, 14(4), 535-562.
[http://dx.doi.org/10.1016/j.jalz.2018.02.018] [PMID: 29653606]

Hampel, H.; Cummings, J.; Blennow, K.; Gao, P.; Jack, C.R., Jr; Vergallo, A. Developing the ATX(N) classification for use across the Alzheime’r disease continuum. Nat. Rev. Neurol., 2021, 17(9), 580-589.
[http://dx.doi.org/10.1038/s41582-021-00520-w] [PMID: 34239130]

Cummings, J.; Lee, G.; Nahed, P.; Kambar, M.E.Z.N.; Zhong, K.; Fonseca, J.; Taghva, K.; Taghva, K. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement., 2022, 8(1), e12295.
[http://dx.doi.org/10.1002/trc2.12295] [PMID: 35516416]

Heneka, M.T.; Carson, M.J.; Khoury, J.E.; Landreth, G.E.; Brosseron, F.; Feinstein, D.L.; Jacobs, A.H.; Wyss-Coray, T.; Vitorica, J.; Ransohoff, R.M.; Herrup, K.; Frautschy, S.A.; Finsen, B.; Brown, G.C.; Verkhratsky, A.; Yamanaka, K.; Koistinaho, J.; Latz, E.; Halle, A.; Petzold, G.C.; Town, T.; Morgan, D.; Shinohara, M.L.; Perry, V.H.; Holmes, C.; Bazan, N.G.; Brooks, D.J.; Hunot, S.; Joseph, B.; Deigendesch, N.; Garaschuk, O.; Boddeke, E.; Dinarello, C.A.; Breitner, J.C.; Cole, G.M.; Golenbock, D.T.; Kummer, M.P. Neuroinflammation in Alzheimer’s disease. Lancet Neurol., 2015, 14(4), 388-405.
[http://dx.doi.org/10.1016/S1474-4422(15)70016-5] [PMID: 25792098]

Minter, M.R.; Taylor, J.M.; Crack, P.J. The contribution of neuroinflammation to amyloid toxicity in Alzheimer’s disease. J. Neurochem., 2016, 136(3), 457-474.
[http://dx.doi.org/10.1111/jnc.13411] [PMID: 26509334]

Nimmerjahn, A.; Kirchhoff, F.; Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science, 2005, 308(5726), 1314-1318.
[http://dx.doi.org/10.1126/science.1110647] [PMID: 15831717]

Anwer, Z.; Gupta, S.P. A QSAR study on a series of pyrrole derivatives acting as lymphocyte-specific kinase (Lck) inhibitors. Med. Chem., 2012, 8(4), 649-655.
[http://dx.doi.org/10.2174/157340612801216319] [PMID: 22548340]

Jha, M.K.; Jo, M.; Kim, J.H.; Suk, K. Microglia-astrocyte crosstalk: An intimate molecular conversation. Neuroscientist, 2019, 25(3), 227-240.
[http://dx.doi.org/10.1177/1073858418783959] [PMID: 29931997]

Karch, C.M.; Goate, A.M. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol. Psychiatry, 2015, 77(1), 43-51.
[http://dx.doi.org/10.1016/j.biopsych.2014.05.006] [PMID: 24951455]

Galatro, T.F.; Holtman, I.R.; Lerario, A.M.; Vainchtein, I.D.; Brouwer, N.; Sola, P.R.; Veras, M.M.; Pereira, T.F.; Leite, R.E.P.; Möller, T.; Wes, P.D.; Sogayar, M.C.; Laman, J.D.; den Dunnen, W.; Pasqualucci, C.A.; Oba-Shinjo, S.M.; Boddeke, E.W.G.M.; Marie, S.K.N.; Eggen, B.J.L. Transcriptomic analysis of purified human cortical microglia reveals age-associated changes. Nat. Neurosci., 2017, 20(8), 1162-1171.
[http://dx.doi.org/10.1038/nn.4597] [PMID: 28671693]

Jay, T.R.; Von Saucken, V.E.; Landreth, G.E. TREM2 in neurodegenerative diseases. Mol. Neurodegener., 2017, 12(1), 1-33.
[http://dx.doi.org/10.1186/s13024-017-0197-5]

Lian, H.; Litvinchuk, A.; Chiang, A.C.A.; Aithmitti, N.; Jankowsky, J.L.; Zheng, H. Astrocyte-microglia cross talk through complement activation modulates amyloid pathology in mouse models of Alzheimer’s disease. J. Neurosci., 2016, 36(2), 577-589.
[http://dx.doi.org/10.1523/JNEUROSCI.2117-15.2016] [PMID: 26758846]

Arranz, A.M.; De Strooper, B. The role of astroglia in Alzheimer’s disease: Pathophysiology and clinical implications. Lancet Neurol., 2019, 18(4), 406-414.
[http://dx.doi.org/10.1016/S1474-4422(18)30490-3] [PMID: 30795987]

Spittau, B. Aging microglia—phenotypes, functions and implications for age-related neurodegenerative diseases. Front. Aging Neurosci., 2017, 9(6), 194.
[http://dx.doi.org/10.3389/fnagi.2017.00194] [PMID: 28659790]

Hanslik, K.L.; Ulland, T.K. The role of microglia and the Nlrp3 inflammasome in Alzheimer’s Disease. Front. Neurol., 2020, 11, 570711.
[http://dx.doi.org/10.3389/fneur.2020.570711] [PMID: 33071950]

Feng, Y.S.; Tan, Z.X.; Wu, L.Y.; Dong, F.; Zhang, F. The involvement of NLRP3 inflammasome in the treatment of Alzheimer’s disease. Ageing Res. Rev., 2020, 64, 101192.
[http://dx.doi.org/10.1016/j.arr.2020.101192] [PMID: 33059089]

Yu, Y.; Ye, R.D. Microglial Aβ receptors in Alzheimer’s disease. Cell. Mol. Neurobiol., 2015, 35(1), 71-83.
[http://dx.doi.org/10.1007/s10571-014-0101-6] [PMID: 25149075]

Li, Y.; Liu, L.; Barger, S.W.; Griffin, W.S.T. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J. Neurosci., 2003, 23(5), 1605-1611.
[http://dx.doi.org/10.1523/JNEUROSCI.23-05-01605.2003] [PMID: 12629164]

Angiulli, F.; Conti, E.; Zoia, C.P.; Da Re, F.; Appollonio, I.; Ferrarese, C.; Tremolizzo, L. Blood-based biomarkers of neuroinflammation in Alzheimer’s disease: A central role for periphery? Diagnostics, 2021, 11(9), 1525.
[http://dx.doi.org/10.3390/diagnostics11091525] [PMID: 34573867]

Hampel, H.; O’Bryant, S.E.; Molinuevo, J.L.; Zetterberg, H.; Masters, C.L.; Lista, S.; Kiddle, S.J.; Batrla, R.; Blennow, K. Blood-based biomarkers for Alzheimer disease: Mapping the road to the clinic. Nat. Rev. Neurol., 2018, 14(11), 639-652.
[http://dx.doi.org/10.1038/s41582-018-0079-7] [PMID: 30297701]

Shen, X.N.; Niu, L.D.; Wang, Y.J.; Cao, X.P.; Liu, Q.; Tan, L.; Zhang, C.; Yu, J.T. Inflammatory markers in Alzheimer’s disease and mild cognitive impairment: A meta-analysis and systematic review of 170 studies. J. Neurol. Neurosurg. Psychiatry, 2019, 90(5), 590-598.
[http://dx.doi.org/10.1136/jnnp-2018-319148] [PMID: 30630955]

Janelidze, S.; Hertze, J.; Zetterberg, H.; Landqvist Waldö, M.; Santillo, A.; Blennow, K.; Hansson, O. Cerebrospinal fluid neurogranin and YKL ‐40 as biomarkers of Alzheimer’s disease. Ann. Clin. Transl. Neurol., 2016, 3(1), 12-20.
[http://dx.doi.org/10.1002/acn3.266] [PMID: 26783546]

Janelidze, S.; Mattsson, N.; Stomrud, E.; Lindberg, O.; Palmqvist, S.; Zetterberg, H.; Blennow, K.; Hansson, O. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology, 2018, 91(9), e867-e877.
[http://dx.doi.org/10.1212/WNL.0000000000006082] [PMID: 30054439]

Jay, T.R.; Miller, C.M.; Cheng, P.J.; Graham, L.C.; Bemiller, S.; Broihier, M.L.; Xu, G.; Margevicius, D.; Karlo, J.C.; Sousa, G.L.; Cotleur, A.C.; Butovsky, O.; Bekris, L.; Staugaitis, S.M.; Leverenz, J.B.; Pimplikar, S.W.; Landreth, G.E.; Howell, G.R.; Ransohoff, R.M.; Lamb, B.T. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models. J. Exp. Med., 2015, 212(3), 287-295.
[http://dx.doi.org/10.1084/jem.20142322] [PMID: 25732305]

Bemiller, S.M.; McCray, T.J.; Allan, K.; Formica, S.V.; Xu, G.; Wilson, G.; Kokiko-Cochran, O.N.; Crish, S.D.; Lasagna-Reeves, C.A.; Ransohoff, R.M.; Landreth, G.E.; Lamb, B.T. TREM2 deficiency exacerbates tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol. Neurodegener., 2017, 12(1), 74.
[http://dx.doi.org/10.1186/s13024-017-0216-6] [PMID: 29037207]

Bao, W.; Xie, F.; Zuo, C.; Guan, Y.; Huang, Y.H. PET neuroimaging of Alzheimer’s Disease: Radiotracers and their utility in clinical research. Front. Aging Neurosci., 2021, 13, 624330.
[http://dx.doi.org/10.3389/fnagi.2021.624330] [PMID: 34025386]

Gaetani, L.; Bellomo, G.; Parnetti, L.; Blennow, K.; Zetterberg, H.; Di Filippo, M. Neuroinflammation and Alzheimer’s Disease: A machine learning approach to CSF proteomics. Cells, 2021, 10(8), 1930.
[http://dx.doi.org/10.3390/cells10081930] [PMID: 34440700]

Bradburn, S.; Murgatroyd, C.; Ray, N. Neuroinflammation in mild cognitive impairment and Alzheimer’s disease: A meta-analysis. Ageing Res. Rev., 2019, 50, 1-8.
[http://dx.doi.org/10.1016/j.arr.2019.01.002] [PMID: 30610927]

Malpetti, M.; Kievit, R.A.; Passamonti, L.; Jones, P.S.; Tsvetanov, K.A.; Rittman, T.; Mak, E.; Nicastro, N.; Bevan-Jones, W.R.; Su, L.; Hong, Y.T.; Fryer, T.D.; Aigbirhio, F.I.; O’Brien, J.T.; Rowe, J.B. Microglial activation and tau burden predict cognitive decline in Alzheimer’s disease. Brain, 2020, 143(5), 1588-1602.
[http://dx.doi.org/10.1093/brain/awaa088] [PMID: 32380523]

Márquez, F.; Yassa, M.A. Neuroimaging biomarkers for Alzheimer’s Disease. Mol. Neurodegener., 2019, 14(1), 1-14.
[http://dx.doi.org/10.1186/s13024-019-0325-5]

Fu, W.Y.; Wang, X.; Ip, N.Y. Targeting neuroinflammation as a therapeutic strategy for Alzheimer’s Disease: Mechanisms, drug candidates, and new opportunities. ACS Chem. Neurosci., 2019, 10(2), 872-879.
[http://dx.doi.org/10.1021/acschemneuro.8b00402] [PMID: 30221933]

Althafar, Z.M. Targeting microglia in Alzheimer’s Disease: From molecular mechanisms to potential therapeutic targets for small molecules. Mol., 2022, 27(13), 4124.
[http://dx.doi.org/10.3390/molecules27134124]

Spangenberg, E.; Severson, P.L.; Hohsfield, L.A.; Crapser, J.; Zhang, J.; Burton, E.A.; Zhang, Y.; Spevak, W.; Lin, J.; Phan, N.Y.; Habets, G.; Rymar, A.; Tsang, G.; Walters, J.; Nespi, M.; Singh, P.; Broome, S.; Ibrahim, P.; Zhang, C.; Bollag, G.; West, B.L.; Green, K.N. Sustained microglial depletion with csf1r inhibitor impairs parenchymal plaque development in an Alzheimer’s Disease model. Nat. Commun., 2019, 10(1), 1-21.
[http://dx.doi.org/10.1038/s41467-019-11674-z]

Sosna, J.; Philipp, S.; Albay, R., III; Reyes-Ruiz, J.M.; Baglietto-Vargas, D.; LaFerla, F.M.; Glabe, C.G. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer’s disease. Mol. Neurodegener., 2018, 13(1), 11.
[http://dx.doi.org/10.1186/s13024-018-0244-x]

Mancuso, R.; Van Den Daele, J.; Fattorelli, N.; Wolfs, L.; Balusu, S.; Burton, O.; Liston, A.; Sierksma, A.; Fourne, Y.; Poovathingal, S.; Arranz-Mendiguren, A.; Sala Frigerio, C.; Claes, C.; Serneels, L.; Theys, T.; Perry, V.H.; Verfaillie, C.; Fiers, M.; De Strooper, B. Stem-cell-derived human microglia transplanted in mouse brain to study human disease. Nat. Neurosci., 2019, 22(12), 2111-2116.
[http://dx.doi.org/10.1038/s41593-019-0525-x]

Muffat, J.; Li, Y.; Yuan, B.; Mitalipova, M.; Omer, A.; Corcoran, S.; Bakiasi, G.; Tsai, L.H.; Aubourg, P.; Ransohoff, R.M.; Jaenisch, R. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat. Med., 2016, 22(11), 1358-1367.
[http://dx.doi.org/10.1038/nm.4189]

Douvaras, P.; Sun, B.; Wang, M.; Kruglikov, I.; Lallos, G.; Zimmer, M.; Terrenoire, C.; Zhang, B.; Gandy, S.; Schadt, E.; Freytes, D.O.; Noggle, S.; Fossati, V. Directed differentiation of human pluripotent stem cells to microglia. Stem Cell Reports, 2017, 8(6), 1516-1524.
[http://dx.doi.org/10.1016/j.stemcr.2017.04.023] [PMID: 28528700]

Price, B.R.; Sudduth, T.L.; Weekman, E.M.; Johnson, S.; Hawthorne, D.; Woolums, A.; Wilcock, D.M. Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition. J. Neuroinflammation, 2020, 17(1), 238.
[http://dx.doi.org/10.1186/s12974-020-01915-0] [PMID: 32795308]

Cheng, Q.; Danao, J.; Talreja, S.; Wen, P.; Yin, J.; Sun, N.; Li, C.M.; Chui, D.; Tran, D.; Koirala, S.; Chen, H.; Foltz, I.N.; Wang, S.; Sambashivan, S. TREM2-activating antibodies abrogate the negative pleiotropic effects of the Alzheimer’s disease variant Trem2R47H on murine myeloid cell function. J. Biol. Chem., 2018, 293(32), 12620-12633.
[http://dx.doi.org/10.1074/jbc.RA118.001848] [PMID: 29599291]

Miles, L.A.; Hermans, S.J.; Crespi, G.A.N.; Gooi, J.H.; Doughty, L.; Nero, T.L. Markulić J.; Ebneth, A.; Wroblowski, B.; Oehlrich, D.; Trabanco, A.A.; Rives, M.L.; Royaux, I.; Hancock, N.C.; Parker, M.W. small molecule binding to alzheimer risk factor CD33 promotes Aβ phagocytosis. iScience, 2019, 19, 110-118.
[http://dx.doi.org/10.1016/j.isci.2019.07.023] [PMID: 31369984]

Zhao, L. CD33 in Alzheimer’s Disease – biology, pathogenesis, and therapeutics: A Mini-Review. Gerontology, 2019, 65(4), 323-331.
[http://dx.doi.org/10.1159/000492596] [PMID: 30541012]

Heneka, M.T.; Sastre, M.; Dumitrescu-Ozimek, L.; Hanke, A.; Dewachter, I.; Kuiperi, C.; O’Banion, K.; Klockgether, T.; Van Leuven, F.; Landreth, G.E. Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice. Brain, 2005, 128(6), 1442-1453.
[http://dx.doi.org/10.1093/brain/awh452] [PMID: 15817521]

Wilkinson, B.L.; Cramer, P.E.; Varvel, N.H.; Reed-Geaghan, E.; Jiang, Q.; Szabo, A.; Herrup, K.; Lamb, B.T.; Landreth, G.E. Ibuprofen attenuates oxidative damage through NOX2 inhibition in Alzheimer’s disease. Neurobiol. Aging, 2012, 33(1), 197.e21-197.e32.
[http://dx.doi.org/10.1016/j.neurobiolaging.2010.06.014] [PMID: 20696495]

Geldmacher, D.S.; Fritsch, T.; McClendon, M.J.; Landreth, G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch. Neurol., 2011, 68(1), 45-50.
[http://dx.doi.org/10.1001/archneurol.2010.229] [PMID: 20837824]

Jiao, S.S.; Yao, X.Q.; Liu, Y.H.; Wang, Q.H.; Zeng, F.; Lu, J.J.; Liu, J.; Zhu, C.; Shen, L.L.; Liu, C.H.; Wang, Y.R.; Zeng, G.H.; Parikh, A.; Chen, J.; Liang, C.R.; Xiang, Y.; Bu, X.L.; Deng, J.; Li, J.; Xu, J.; Zeng, Y.Q.; Xu, X.; Xu, H.W.; Zhong, J.H.; Zhou, H.D.; Zhou, X.F.; Wang, Y.J. Edaravone alleviates Alzheimer’s Disease-type pathologies and cognitive deficits. Proc. Natl. Acad. Sci. USA, 2015, 112(16), 5225-5230.
[http://dx.doi.org/10.1073/pnas.1422998112] [PMID: 25847999]

Parikh, A.; Kathawala, K.; Li, J.; Chen, C.; Shan, Z.; Cao, X.; Wang, Y.J.; Garg, S.; Zhou, X.F. Self-nanomicellizing solid dispersion of edaravone: part II: In vivo assessment of efficacy against behavior deficits and safety in Alzheimer’s Disease model. Drug Des. Devel. Ther., 2018, 12, 2111-2128.
[http://dx.doi.org/10.2147/DDDT.S161944] [PMID: 30022810]

Howard, R.; Zubko, O.; Bradley, R.; Harper, E.; Pank, L.; O’Brien, J.; Fox, C.; Tabet, N.; Livingston, G.; Bentham, P.; McShane, R.; Burns, A.; Ritchie, C.; Reeves, S.; Lovestone, S.; Ballard, C.; Noble, W.; Nilforooshan, R.; Wilcock, G.; Gray, R. Minocycline at 2 different dosages vs. placebo for patients with mild alzheimer disease. JAMA Neurol., 2020, 77(2), 164-174.
[http://dx.doi.org/10.1001/jamaneurol.2019.3762] [PMID: 31738372]

Sharif, N.A. Degeneration of retina-brain components and connections in glaucoma: Disease causation and treatment options for eyesight preservation. Curr. Res. Neurobiol., 2022, 3, 100037.
[http://dx.doi.org/10.1016/j.crneur.2022.100037]

Thawkar, B.S.; Kaur, G. Inhibitors of NF-κB and P2X7/NLRP3/Caspase 1 pathway in microglia: Novel therapeutic opportunities in neuroinflammation induced early-stage Alzheimer’s disease. J. Neuroimmunol., 2019, 326, 62-74.
[http://dx.doi.org/10.1016/j.jneuroim.2018.11.010] [PMID: 30502599]

Illes, P. P2X7 Receptors amplify CNS damage in neurodegenerative diseases. Int. J. Mol. Sci., 2020, 21(17), 5996.
[http://dx.doi.org/10.3390/ijms21175996] [PMID: 32825423]

Stewart, W.F.; Kawas, C.; Corrada, M.; Metter, E.J. Risk of Alzheimer’s disease and duration of NSAID use. Neurology, 1997, 48(3), 626-632.
[http://dx.doi.org/10.1212/WNL.48.3.626] [PMID: 9065537]

Zandi, P.P.; Anthony, J.C.; Hayden, K.M.; Mehta, K.; Mayer, L.; Breitner, J.C.S. Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study. Neurology, 2002, 59(6), 880-886.
[http://dx.doi.org/10.1212/WNL.59.6.880] [PMID: 12297571]

Szekely, C.A.; Breitner, J.C.S.; Fitzpatrick, A.L.; Rea, T.D.; Psaty, B.M.; Kuller, L.H.; Zandi, P.P. NSAID use and dementia risk in the Cardiovascular Health Study: Role of APOE and NSAID type. Neurology, 2008, 70(1), 17-24.
[http://dx.doi.org/10.1212/01.wnl.0000284596.95156.48] [PMID: 18003940]

In ’T Veld, B. A.; Launer, L. J.; Hoes, A. W.; Ott, A.; Hofman, A.; Breteler, M. M. B.; Stricker, B. H. C. NSAIDs and Incident Alzheimer’s Disease. The Rotterdam Study. Neurobiol. Aging, 1998, 19(6), 607-611.
[http://dx.doi.org/10.1016/S0197-4580(98)00096-7] [PMID: 10192221]

Yip, A.G.; Green, R.C.; Huyck, M.; Cupples, L.A.; Farrer, L.A. Nonsteroidal anti-inflammatory drug use and Alzheimer’s Disease risk: the MIRAGE Study. BMC Geriatr., 2005, 5(1), 2.
[http://dx.doi.org/10.1186/1471-2318-5-2] [PMID: 15647106]

Mc Dowell, I.; Hill, G.; Lindsay, J.; Helliwell, B.; Costa, L.; Beattie, L.; Hertzman, C.; Tuokko, H.; Gutman, G.; Parhad, I.; Parboosingh, J.; Bland, R.; Newman, S.; Dobbs, A.; Hazlett, C.; Rule, B.; D’arcy, C.; Segall, A.; Chappell, N.; Manfreda, J.; Montgomery, P.; Østbye, T.; Robertson, J.; Hachinski, V.; Chambers, L.; Eastwood, R.; Rifat, S.; Verdon, J.; Nauarro, J.; Gauthier, S.; Wolfson, C.; Baumgarten, M.; Ska, B.; Joanette, Y.; Kergoat, M.J.; Nazerali, N.; Hébert, R.; Bravo, G.; Doyon, J.; Bouchard, R.; Morin, J.; Gauureau, D.; Balram, C.; Rockwood, K.; Gray, J.; Fisk, J.; Nilsson, T.; Donald, A.; Buehler, S.; Pryse-Phillips, W.; Kozma, A. The Canadian Study of Health and Aging: Risk factors for Alzheimer’s disease in Canada. Neurology, 1994, 44(11), 2073-2080.
[http://dx.doi.org/10.1212/WNL.44.11.2073] [PMID: 7969962]

Zhang, C.; Wang, Y.; Wang, D.; Zhang, J.; Zhang, F. NSAID exposure and risk of Alzheimer’s Disease: An updated meta-analysis from cohort studies. Front. Aging Neurosci., 2018, 10(3), 83.
[http://dx.doi.org/10.3389/fnagi.2018.00083] [PMID: 29643804]

Pasinetti, G.M. From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer’s disease: The role of NSAIDs and cyclooxygenase in β-amyloidosis and clinical dementia1. J. Alzheimers Dis., 2002, 4(5), 435-445.
[http://dx.doi.org/10.3233/JAD-2002-4510] [PMID: 12446975]

Liu, P.; Wang, Y.; Sun, Y.; Peng, G. Neuroinflammation as a Potential Therapeutic Target in Alzheimer’s Disease. Clin. Interv. Aging, 2022, 17, 665-674.
[http://dx.doi.org/10.2147/CIA.S357558] [PMID: 35520949]

Puhl, A.C.; Milton, F.A.; Cvoro, A.; Sieglaff, D.H.; Campos, J.C.L.; Bernardes, A.; Filgueira, C.S.; Lindemann, J.L.; Deng, T.; Neves, F.A.R.; Polikarpov, I.; Webb, P. Mechanisms of peroxisome proliferator activated receptor γ regulation by non-steroidal anti-inflammatory drugs. Nucl. Recept. Signal., 2015, 13(1), nrs.13004.
[http://dx.doi.org/10.1621/nrs.13004] [PMID: 26445566]

Athar, T.; Al Balushi, K.; Khan, S.A. Recent advances on drug development and emerging therapeutic agents for Alzheimer’s Disease. Mol. Biol. Rep., 2021, 48(7), 5629-5645.
[http://dx.doi.org/10.1007/s11033-021-06512-9] [PMID: 34181171]

Albertini, C.; Naldi, M.; Petralla, S.; Strocchi, S.; Grifoni, D.; Monti, B.; Bartolini, M.; Bolognesi, M.L. From combinations to single-molecule polypharmacology—cromolyn-ibuprofen conjugates for Alzheimer’s Disease. Mol., 2021, 26(4), 1112.
[http://dx.doi.org/10.3390/molecules26041112]

Sano, M.; Ernesto, C.; Thomas, R.G.; Klauber, M.R.; Schafer, K.; Grundman, M.; Woodbury, P.; Growdon, J.; Cotman, C.W.; Pfeiffer, E.; Schneider, L.S.; Thal, L.J. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s Disease. The Alzheimer’s Disease Cooperative Study. N. Engl. J. Med., 1997, 336(17), 1216-1222.
[http://dx.doi.org/10.1056/NEJM199704243361704] [PMID: 9110909]

Galluzzi, S.; Zanetti, O.; Binetti, G.; Trabucchi, M.; Frisoni, G.B. Coma in a patient with Alzheimer’s disease taking low dose trazodone and ginkgo biloba. J. Neurol. Neurosurg. Psychiatry, 2000, 68(5), 679a-680.
[http://dx.doi.org/10.1136/jnnp.68.5.679a] [PMID: 10836866]

SanMartín, C.D.; Henriquez, M.; Chacon, C.; Ponce, D.P.; Salech, F.; Rogers, N.K.; Behrens, M.I.; Vitamin, D. Vitamin D increases Aβ140 plasma levels and protects lymphocytes from oxidative death in mild cognitive impairment patients. Curr. Alzheimer Res., 2018, 15(6), 561-569.
[http://dx.doi.org/10.2174/1567205015666171227154636] [PMID: 29283046]

Annweiler, C.; Herrmann, F.R.; Fantino, B.; Brugg, B.; Beauchet, O. Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: A pre-post pilot study. Cogn. Behav. Neurol., 2012, 25(3), 121-127.
[http://dx.doi.org/10.1097/WNN.0b013e31826df647] [PMID: 22960436]

Kontush, A.; Mann, U.; Arlt, S.; Ujeyl, A.; Lührs, C.; Müller-Thomsen, T.; Beisiegel, U. Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer’s disease. Free Radic. Biol. Med., 2001, 31(3), 345-354.
[http://dx.doi.org/10.1016/S0891-5849(01)00595-0] [PMID: 11461772]

Dysken, M.W.; Sano, M.; Asthana, S.; Vertrees, J.E.; Pallaki, M.; Llorente, M.; Love, S.; Schellenberg, G.D.; McCarten, J.R.; Malphurs, J.; Prieto, S.; Chen, P.; Loreck, D.J.; Trapp, G.; Bakshi, R.S.; Mintzer, J.E.; Heidebrink, J.L.; Vidal-Cardona, A.; Arroyo, L.M.; Cruz, A.R.; Zachariah, S.; Kowall, N.W.; Chopra, M.P.; Craft, S.; Thielke, S.; Turvey, C.L.; Woodman, C.; Monnell, K.A.; Gordon, K.; Tomaska, J.; Segal, Y.; Peduzzi, P.N.; Guarino, P.D. Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA, 2014, 311(1), 33-44.
[http://dx.doi.org/10.1001/jama.2013.282834] [PMID: 24381967]

Zhu, M.; Hao, S.; Liu, T.; Yang, L.; Zheng, P.; Zhang, L.; Ji, G. Lingguizhugan decoction improves non-alcoholic fatty liver disease by altering insulin resistance and lipid metabolism related genes: A whole trancriptome study by RNA-Seq. Oncotarget, 2017, 8(47), 82621-82631.
[http://dx.doi.org/10.18632/oncotarget.19734] [PMID: 29137289]

Breitner, J.; Baker, L.; Drye, L.; Evans, D.; Lyketsos, C.G.; Ryan, L.; Zandi, P.; Saucedo, H.H.; Anau, J.; Cholerton, B. Follow‐up evaluation of cognitive function in the randomized Alzheimer’s Disease Anti‐inflammatory Prevention Trial and its Follow‐up Study. Alzheimers Dement., 2015, 11(2), 216-25.e1.
[http://dx.doi.org/10.1016/j.jalz.2014.03.009] [PMID: 25022541]

Butchart, J.; Brook, L.; Hopkins, V.; Teeling, J.; Püntener, U.; Culliford, D.; Sharples, R.; Sharif, S.; McFarlane, B.; Raybould, R.; Thomas, R.; Passmore, P.; Perry, V.H.; Holmes, C. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology, 2015, 84(21), 2161-2168.
[http://dx.doi.org/10.1212/WNL.0000000000001617] [PMID: 25934853]

Najem, D.; Bamji-Mirza, M.; Chang, N.; Liu, Q.Y.; Zhang, W. Insulin resistance, neuroinflammation, and Alzheimer’s disease. Rev. Neurosci., 2014, 25(4), 509-525.
[http://dx.doi.org/10.1515/revneuro-2013-0050] [PMID: 24622783]

El-Shiekh, R.A.; Ashour, R.M.; Abd El-Haleim, E.A.; Ahmed, K.A.; Abdel-Sattar, E. Hibiscus sabdariffa L.: A potent natural neuroprotective agent for the prevention of streptozotocin-induced Alzheimer’s disease in mice. Biomed. Pharmacother., 2020, 128(5), 110303.
[http://dx.doi.org/10.1016/j.biopha.2020.110303] [PMID: 32480228]

Combs, C.K.; Karlo, J.C.; Kao, S.C.; Landreth, G.E. beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci., 2001, 21(4), 1179-1188.
[http://dx.doi.org/10.1523/JNEUROSCI.21-04-01179.2001] [PMID: 11160388]

Liao, Y.F.; Wang, B.J.; Cheng, H.T.; Kuo, L.H.; Wolfe, M.S. Tumor necrosis factor-α interleukin-1β and interferon-γ stimulate γ-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J. Biol. Chem., 2004, 279(47), 49523-49532.
[http://dx.doi.org/10.1074/jbc.M402034200] [PMID: 15347683]

Chen, G.; Goeddel, D.V. TNF-R1 signaling: A beautiful pathway. Science, 2002, 296(5573), 1634-1635.
[http://dx.doi.org/10.1126/science.1071924] [PMID: 12040173]

Torres-Acosta, N.; O’Keefe, J.H.; O’Keefe, E.L.; Isaacson, R.; Small, G. Therapeutic Potential of TNF-α Inhibition for Alzheimer’s Disease Prevention. J. Alzheimers Dis., 2020, 78(2), 619-626.
[http://dx.doi.org/10.3233/JAD-200711] [PMID: 33016914]

Shi, J.Q.; Shen, W.; Chen, J.; Wang, B.R.; Zhong, L.L.; Zhu, Y.W.; Zhu, H.Q.; Zhang, Q.Q.; Zhang, Y.D.; Xu, J. Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res., 2011, 1368, 239-247.
[http://dx.doi.org/10.1016/j.brainres.2010.10.053] [PMID: 20971085]

Kim, D.H.; Choi, S.M.; Jho, J.; Park, M.S.; Kang, J.; Park, S.J.; Ryu, J.H.; Jo, J.; Kim, H.H.; Kim, B.C. Infliximab ameliorates AD-associated object recognition memory impairment. Behav. Brain Res., 2016, 311, 384-391.
[http://dx.doi.org/10.1016/j.bbr.2016.06.001] [PMID: 27265784]

Ou, W.; Yang, J.; Simanauskaite, J.; Choi, M.; Castellanos, D.M.; Chang, R.; Sun, J.; Jagadeesan, N.; Parfitt, K.D.; Cribbs, D.H.; Sumbria, R.K. Biologic TNF-α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy. J. Neuroinflam., 2021, 18(1), 312.
[http://dx.doi.org/10.1186/s12974-021-02332-7] [PMID: 34972522]

Boado, R.J.; Hui, E.K.W.; Lu, J.Z.; Zhou, Q.H.; Pardridge, W.M. Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein. J. Biotechnol., 2010, 146(1-2), 84-91.
[http://dx.doi.org/10.1016/j.jbiotec.2010.01.011] [PMID: 20100527]

Tobinick, E.; Gross, H.; Weinberger, A.; Cohen, H. TNF-alpha modulation for treatment of Alzheimer’s Disease: A 6-month pilot study. MedGenMed, 2006, 8(2), 25.
[PMID: 16926764]

Atigari, O.V.; Healy, D. Schizophrenia-like disorder associated with etanercept treatment. BMJ Case Rep., 2014, 2014(1), bcr2013200464.
[http://dx.doi.org/10.1136/bcr-2013-200464] [PMID: 24419811]

Roerink, M.E.; Groen, R.J.M.; Franssen, G.; Lemmers-van de Weem, B.; Boerman, O.C.; van der Meer, J.W.M. Central delivery of iodine-125–labeled cetuximab, etanercept and anakinra after perispinal injection in rats: Possible implications for treating Alzheimer’s disease. Alzheimers Res. Ther., 2015, 7(1), 70.
[http://dx.doi.org/10.1186/s13195-015-0149-7] [PMID: 26560086]

Zhou, M.; Xu, R.; Kaelber, D.C.; Gurney, M.E. Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis. PLoS One, 2020, 15(3), e0229819.
[http://dx.doi.org/10.1371/journal.pone.0229819] [PMID: 32203525]

Dong, Y.; Fischer, R.; Naudé, P.J.W.; Maier, O.; Nyakas, C.; Duffey, M.; Van der Zee, E.A.; Dekens, D.; Douwenga, W.; Herrmann, A.; Guenzi, E.; Kontermann, R.E.; Pfizenmaier, K.; Eisel, U.L.M. Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration. Proc. Natl. Acad. Sci., 2016, 113(43), 12304-12309.
[http://dx.doi.org/10.1073/pnas.1605195113] [PMID: 27791020]

MacPherson, K.P.; Sompol, P.; Kannarkat, G.T.; Chang, J.; Sniffen, L.; Wildner, M.E.; Norris, C.M.; Tansey, M.G. Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice. Neurobiol. Dis., 2017, 102, 81-95.
[http://dx.doi.org/10.1016/j.nbd.2017.02.010] [PMID: 28237313]

Vieira, M. N. N.; Lima-Filho, R. A. S.; De Felice, F. G. Connecting Alzheimer’s Disease to diabetes: Underlying mechanisms and potential therapeutic targets. Neuropharmacology, 2018, 136(Pt B), 160-171.
[http://dx.doi.org/10.1016/j.neuropharm.2017.11.014]

Frisardi, V.; Solfrizzi, V.; Seripa, D.; Capurso, C.; Santamato, A.; Sancarlo, D.; Vendemiale, G.; Pilotto, A.; Panza, F. Metabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer’s disease. Ageing Res. Rev., 2010, 9(4), 399-417.
[http://dx.doi.org/10.1016/j.arr.2010.04.007] [PMID: 20444434]

Kullmann, S.; Heni, M.; Hallschmid, M.; Fritsche, A.; Preissl, H.; Häring, H.U. Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans. Physiol. Rev., 2016, 96(4), 1169-1209.
[http://dx.doi.org/10.1152/physrev.00032.2015] [PMID: 27489306]

Kianpour Rad, S.; Arya, A.; Karimian, H.; Madhavan, P.; Rizwan, F.; Koshy, S.; Prabhu, G. Mechanism involved in insulin resistance via accumulation of β-amyloid and neurofibrillary tangles: Link between type 2 diabetes and Alzheimer’s Disease. Drug Des. Devel. Ther., 2018, 12, 3999-4021.
[http://dx.doi.org/10.2147/DDDT.S173970] [PMID: 30538427]

Marciniak, E.; Leboucher, A.; Caron, E.; Ahmed, T.; Tailleux, A.; Dumont, J.; Issad, T.; Gerhardt, E.; Pagesy, P.; Vileno, M.; Bournonville, C.; Hamdane, M.; Bantubungi, K.; Lancel, S.; Demeyer, D.; Eddarkaoui, S.; Vallez, E.; Vieau, D.; Humez, S.; Faivre, E.; Grenier-Boley, B.; Outeiro, T.F.; Staels, B.; Amouyel, P.; Balschun, D.; Buee, L.; Blum, D. Tau deletion promotes brain insulin resistance. J. Exp. Med., 2017, 214(8), 2257-2269.
[http://dx.doi.org/10.1084/jem.20161731] [PMID: 28652303]

Rodriguez-Rodriguez, P.; Sandebring-Matton, A.; Merino-Serrais, P.; Parrado-Fernandez, C.; Rabano, A.; Winblad, B.; Ávila, J.; Ferrer, I.; Cedazo-Minguez, A. Tau hyperphosphorylation induces oligomeric insulin accumulation and insulin resistance in neurons. Brain, 2017, 140(12), 3269-3285.
[http://dx.doi.org/10.1093/brain/awx256] [PMID: 29053786]

Luque-Contreras, D.; Carvajal, K.; Toral-Rios, D.; Franco-Bocanegra, D.; Campos-Peña, V. Oxidative stress and metabolic syndrome: cause or consequence of Alzheimer’s Disease? Oxid. Med. Cell. Longev., 2014, 2014, 1-11.
[http://dx.doi.org/10.1155/2014/497802] [PMID: 24683436]

De Felice, F.G.; Lourenco, M.V.; Ferreira, S.T. How does brain insulin resistance develop in Alzheimer’s Disease? Alzheimers Dement., 2014, 10(1S)(Suppl.), S26-S32.
[http://dx.doi.org/10.1016/j.jalz.2013.12.004] [PMID: 24529521]

Zhou, Y.L.; Du, Y.F.; Du, H.; Shao, P. Insulin resistance in Alzheimer’s disease (AD) mouse intestinal macrophages is mediated by activation of JNK. Eur. Rev. Med. Pharmacol. Sci., 2017, 21(8), 1787-1794.
[PMID: 28485801]

Peng, Y.; Gao, P.; Shi, L.; Chen, L.; Liu, J.; Long, J. Central and peripheral metabolic defects contribute to the pathogenesis of alzheimer’s disease: Targeting mitochondria for diagnosis and prevention. Antioxid. Redox Signal., 2020, 32(16), 1188-1236.
[http://dx.doi.org/10.1089/ars.2019.7763] [PMID: 32050773]

Kinney, J.W.; Bemiller, S.M.; Murtishaw, A.S.; Leisgang, A.M.; Salazar, A.M.; Lamb, B.T. Inflammation as a central mechanism in Alzheimer’s Disease. Alzheimers Dement., 2018, 4(1), 575-590.
[http://dx.doi.org/10.1016/j.trci.2018.06.014] [PMID: 30406177]

Spinelli, M.; Fusco, S.; Grassi, C. Brain insulin resistance and hippocampal plasticity: Mechanisms and biomarkers of cognitive decline. Front. Neurosci., 2019, 13, 788.
[http://dx.doi.org/10.3389/fnins.2019.00788] [PMID: 31417349]

Kern, W.; Peters, A.; Fruehwald-Schultes, B.; Deininger, E.; Born, J.; Fehm, H.L. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology, 2001, 74(4), 270-280.
[http://dx.doi.org/10.1159/000054694] [PMID: 11598383]

Kern, W.; Born, J.; Schreiber, H.; Fehm, H.L. Central nervous system effects of intranasally administered insulin during euglycemia in men. Diabetes, 1999, 48(3), 557-563.
[http://dx.doi.org/10.2337/diabetes.48.3.557] [PMID: 10078556]

Avgerinos, K.I.; Kalaitzidis, G.; Malli, A.; Kalaitzoglou, D.; Myserlis, P.G.; Lioutas, V.A. Intranasal insulin in Alzheimer’s Dementia or mild cognitive impairment: A systematic review. J. Neurol., 2018, 265(7), 1497-1510.
[http://dx.doi.org/10.1007/s00415-018-8768-0] [PMID: 29392460]

Kamal, R.M.; Razis, A.F.A.; Sukri, N.S.M.; Perimal, E.K.; Ahmad, H.; Patrick, R.; Djedaini-Pilard, F.; Mazzon, E.; Rigaud, S. Beneficial health effects of glucosinolates-derived isothiocyanates on cardiovascular and neurodegenerative diseases. Mol., 2022, 27(3), 624.
[http://dx.doi.org/10.3390/molecules27030624]

Candeias, E.M.; Sebastião, I.C.; Cardoso, S.M.; Correia, S.C.; Carvalho, C.I.; Plácido, A.I.; Santos, M.S.; Oliveira, C.R.; Moreira, P.I.; Duarte, A.I. Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide. World J. Diabetes, 2015, 6(6), 807-827.
[http://dx.doi.org/10.4239/wjd.v6.i6.807] [PMID: 26131323]

Makita, K.; Takahashi, K.; Karara, A.; Jacobson, H.R.; Falck, J.R.; Capdevila, J.H. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J. Clin. Invest., 1994, 94(6), 2414-2420.
[http://dx.doi.org/10.1172/JCI117608] [PMID: 7989598]

Gault, V.A.; Porter, W.D.; Flatt, P.R.; Hölscher, C. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. Int. J. Obes., 2010, 34(8), 1341-1344.
[http://dx.doi.org/10.1038/ijo.2010.59] [PMID: 20351729]

Hamilton, A.; Patterson, S.; Porter, D.; Gault, V.A.; Holscher, C. Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J. Neurosci. Res., 2011, 89(4), 481-489.
[http://dx.doi.org/10.1002/jnr.22565] [PMID: 21312223]

Gold, M.; Alderton, C.; Zvartau-Hind, M.; Egginton, S.; Saunders, A.M.; Irizarry, M.; Craft, S.; Landreth, G.; Linnamägi, Ü.; Sawchak, S. Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: Results from a randomized, double-blind, placebo-controlled phase III study. Dement. Geriatr. Cogn. Disord., 2010, 30(2), 131-146.
[http://dx.doi.org/10.1159/000318845] [PMID: 20733306]

Harrington, C.; Sawchak, S.; Chiang, C.; Davies, J.; Donovan, C.; Saunders, A.M.; Irizarry, M.; Jeter, B.; Zvartau-Hind, M.; van Dyck, C.H.; Gold, M. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer’s disease: Two phase 3 studies. Curr. Alzheimer Res., 2011, 8(5), 592-606.
[http://dx.doi.org/10.2174/156720511796391935] [PMID: 21592048]

Koenig, A.M.; Mechanic-Hamilton, D.; Xie, S.X.; Combs, M.F.; Cappola, A.R.; Xie, L.; Detre, J.A.; Wolk, D.A.; Arnold, S.E. Effects of the Insulin Sensitizer Metformin in Alzheimer Disease. Alzheimer Dis. Assoc. Disord., 2017, 31(2), 107-113.
[http://dx.doi.org/10.1097/WAD.0000000000000202] [PMID: 28538088]

Rivera, P.; Fernández-Arjona, M.M.; Silva-Peña, D.; Blanco, E.; Vargas, A.; López-Ávalos, M.D.; Grondona, J.M.; Serrano, A.; Pavón, F.J.; Rodríguez de Fonseca, F.; Suárez, J. Pharmacological blockade of fatty acid amide hydrolase (FAAH) by URB597 improves memory and changes the phenotype of hippocampal microglia despite ethanol exposure. Biochem. Pharmacol., 2018, 157, 244-257.
[http://dx.doi.org/10.1016/j.bcp.2018.08.005] [PMID: 30098312]

Mulder, J.; Zilberter, M.; Pasquaré, S.J.; Alpár, A.; Schulte, G.; Ferreira, S.G.; Köfalvi, A.; Martín-Moreno, A.M.; Keimpema, E.; Tanila, H.; Watanabe, M.; Mackie, K.; Hortobágyi, T.; de Ceballos, M.L.; Harkany, T. Molecular reorganization of endocannabinoid signalling in Alzheimer’s Disease. Brain, 2011, 134(4), 1041-1060.
[http://dx.doi.org/10.1093/brain/awr046] [PMID: 21459826]

Mohamed, W.A.; Salama, R.M.; Schaalan, M.F. A pilot study on the effect of lactoferrin on Alzheimer’s Disease pathological sequelae: Impact of the p-Akt/PTEN pathway. Biomed. Pharmacother., 2019, 111(111), 714-723.
[http://dx.doi.org/10.1016/j.biopha.2018.12.118] [PMID: 30611996]

Abdelhamid, M.; Jung, C.G.; Zhou, C.; Abdullah, M.; Nakano, M.; Wakabayashi, H.; Abe, F.; Michikawa, M. Dietary lactoferrin supplementation prevents memory impairment and reduces amyloid-β generation in J20 mice. J. Alzheimers Dis., 2020, 74(1), 245-259.
[http://dx.doi.org/10.3233/JAD-191181] [PMID: 31985470]

Wink, M.; Ashour, M.L.; Youssef, F.S.; Gad, H.A. Inhibition of cytochrome P450 (CYP3A4) activity by extracts from 57 plants used in traditional chinese medicine (TCM). Pharmacogn. Mag., 2017, 13(50), 300-308.
[http://dx.doi.org/10.4103/0973-1296.204561] [PMID: 28539725]

Staehelin, H.B. Micronutrients and Alzheimer’s Disease. Proc. Nutr. Soc., 2005, 64(4), 565-570.
[http://dx.doi.org/10.1079/PNS2005459] [PMID: 16313699]

Cichon, N.; Dziedzic, A.; Gorniak, L.; Miller, E.; Bijak, M.; Starosta, M.; Saluk-Bijak, J. Unusual bioactive compounds with antioxidant properties in adjuvant therapy supporting cognition impairment in age-related neurodegenerative disorders. Int. J. Mol. Sci., 2021, 22(19), 10707.
[http://dx.doi.org/10.3390/ijms221910707] [PMID: 34639048]

Liu, J.; Li, H.; Gong, T.; Chen, W.; Mao, S.; Kong, Y.; Yu, J.; Sun, J. Anti-neuroinflammatory effect of short-chain fatty acid acetate against Alzheimer’s Disease via upregulating GPR41 and Inhibiting ERK/JNK/NF-κ. B. J. Agric. Food Chem., 2020, 68(27), 7152-7161.
[http://dx.doi.org/10.1021/acs.jafc.0c02807] [PMID: 32583667]

Vashistha, P.; Zahra, K.; Kumar, A.; Kumar, T.; Srivastava, M.; Mishra, S.P. Is there a correlation between micronutrients and cognitive status: an exploratory study of senile dementia of Alzheimer’s Type. J. Clin. Diagn. Res., 2018, 12(4), BC01-BC04.
[http://dx.doi.org/10.7860/JCDR/2018/32236.11376]

Park, S.; Kang, S.; Sol Kim, D. Folate and vitamin B-12 deficiencies additively impaire memory function and disturb the gut microbiota in amyloid-β infused rats. Int. J. Vitam. Nutr. Res., 2022, 92(3-4), 169-181.
[http://dx.doi.org/10.1024/0300-9831/a000624] [PMID: 31841076]

Ma, F.; Zhou, X.; Li, Q.; Zhao, J.; Song, A.; An, P.; Du, Y.; Xu, W.; Huang, G. Effects of folic acid and vitamin B12, alone and in combination on cognitive function and inflammatory factors in the elderly with mild cognitive impairment: A single-blind experimental design. Curr. Alzheimer Res., 2019, 16(7), 622-632.
[http://dx.doi.org/10.2174/1567205016666190725144629] [PMID: 31345146]

Vakilian, A.; Razavi-Nasab, S.M.; Ravari, A.; Mirzaei, T.; Moghadam-Ahmadi, A.; Jalali, N.; Bahramabadi, R.; Rezayati, M.; Yazdanpanah-Ravari, A.; Bahmaniar, F.; Bagheri, M.R.; Sheikh Fathollahi, M.; Asadikaram, G. Kazemi arababadi, m. vitamin B12 in association with antipsychotic drugs can modulate the expression of pro-/anti-inflammatory cytokines in Alzheimer Disease Patients. Neuroimmunomodulation, 2017, 24(6), 310-319.
[http://dx.doi.org/10.1159/000486597] [PMID: 29558759]

Bahramabadi, R.; Samadi, M.; Vakilian, A.; Jafari, E.; Fathollahi, M.S.; Arababadi, M.K. Evaluation of the effects of anti-psychotic drugs on the expression of CD68 on the peripheral blood monocytes of Alzheimer patients with psychotic symptoms. Life Sci., 2017, 179, 73-79.
[http://dx.doi.org/10.1016/j.lfs.2017.04.024] [PMID: 28465247]

Ramprasad, M.P.; Terpstra, V.; Kondratenko, N.; Quehenberger, O.; Steinberg, D. Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA, 1996, 93(25), 14833-14838.
[http://dx.doi.org/10.1073/pnas.93.25.14833] [PMID: 8962141]

Cabezas-Cerrato, J.; Garcia-Estevez, D.A.; Araújo, D.; Iglesias, M. Insulin sensitivity, glucose effectiveness, and β-cell function in obese males with essential hypertension: Investigation of the effects of treatment with a calcium channel blocker (diltiazem) or an angiotensin-converting enzyme inhibitor (quinapril). Metabolism, 1997, 46(2), 173-178.
[http://dx.doi.org/10.1016/S0026-0495(97)90298-5] [PMID: 9030825]

Farah, R.; Khamisy-Farah, R.; Shurtz-Swirski, R. Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients. Int. Angiol., 2013, 32(1), 85-93.
[PMID: 23435396]

Li, X.; Wang, L.; Gao, X.; Li, G.; Cao, H.; Song, D.; Cai, S.; Liang, T.; Zhang, B.; Du, G. Mechanisms of protective effect of ramulus mori polysaccharides on renal injury in high-fat diet/streptozotocin-induced diabetic rats. Cell. Physiol. Biochem., 2015, 37(6), 2125-2134.
[http://dx.doi.org/10.1159/000438570] [PMID: 26599870]

Schmidt, M.E.; Liebowitz, M.R.; Stein, M.B.; Grunfeld, J.; Van Hove, I.; Simmons, W.K.; Van Der Ark, P.; Palmer, J.A.; Saad, Z.S.; Pemberton, D.J.; Van Nueten, L.; Drevets, W.C. The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: A double-blind, randomized, placebo-controlled proof-of-concept study. Neuropsychopharmacology, 2021, 46(5), 1004-1010.
[http://dx.doi.org/10.1038/s41386-020-00888-1] [PMID: 33070154]

Lawlor, B.; Segurado, R.; Kennelly, S.; Olde Rikkert, M.G.M.; Howard, R.; Pasquier, F.; Börjesson-Hanson, A.; Tsolaki, M.; Lucca, U.; Molloy, D.W.; Coen, R.; Riepe, M.W.; Kálmán, J.; Kenny, R.A.; Cregg, F.; O’Dwyer, S.; Walsh, C.; Adams, J.; Banzi, R.; Breuilh, L.; Daly, L.; Hendrix, S.; Aisen, P.; Gaynor, S.; Sheikhi, A.; Taekema, D.G.; Verhey, F.R.; Nemni, R.; Nobili, F.; Franceschi, M.; Frisoni, G.; Zanetti, O.; Konsta, A.; Anastasios, O.; Nenopoulou, S.; Tsolaki-Tagaraki, F.; Pakaski, M.; Dereeper, O.; de la Sayette, V.; Sénéchal, O.; Lavenu, I.; Devendeville, A.; Calais, G.; Crawford, F.; Mullan, M. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Med., 2018, 15(9), e1002660.
[http://dx.doi.org/10.1371/journal.pmed.1002660] [PMID: 30248105]

Huang, W.; Li, Z.; Zhao, L.; Zhao, W. Simvastatin ameliorate memory deficits and inflammation in clinical and mouse model of Alzheimer’s disease via modulating the expression of miR-106b. Biomed. Pharmacother., 2017, 92, 46-57.
[http://dx.doi.org/10.1016/j.biopha.2017.05.060] [PMID: 28528185]

Zhao, L.; Zhao, Q.; Zhou, Y.; Zhao, Y.; Wan, Q. Atorvastatin may correct dyslipidemia in adult patients at risk for alzheimer’s disease through an anti-inflammatory pathway. CNS Neurol. Disord. Drug Targets, 2016, 15(1), 80-85.
[http://dx.doi.org/10.2174/1871527315999160111160143] [PMID: 26666876]

Ferrari, J. Randomized Controlled Trial of Atorvastatin in Mild to Moderate Alzheimer Disease: LEADe. J. Neurol. Neurochir. Psychiatr., 2010, 11(4), 85.

Poly, T.N.; Islam, M.M.; Walther, B.A.; Yang, H.C.; Wu, C.C.; Lin, M.C.; Li, Y.C. Association between use of statin and risk of dementia: A meta-analysis of observational studies. Neuroepidemiology, 2020, 54(3), 214-226.
[http://dx.doi.org/10.1159/000503105] [PMID: 31574510]

Sano, M.; Bell, K.L.; Galasko, D.; Galvin, J.E.; Thomas, R.G.; van Dyck, C.H.; Aisen, P.S. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology, 2011, 77(6), 556-563.
[http://dx.doi.org/10.1212/WNL.0b013e318228bf11] [PMID: 21795660]

Lin, Z.; Vicente Gonçalves, C.M.; Dai, L.; Lu, H.; Huang, J.; Ji, H.; Wang, D.; Yi, L.; Liang, Y. Exploring metabolic syndrome serum profiling based on gas chromatography mass spectrometry and random forest models. Anal. Chim. Acta, 2014, 827, 22-27.
[http://dx.doi.org/10.1016/j.aca.2014.04.008] [PMID: 24832990]

van den Elsen, G.A.H.; Ahmed, A.I.A.; Verkes, R.J.; Kramers, C.; Feuth, T.; Rosenberg, P.B.; van der Marck, M.A.; Olde Rikkert, M.G.M.; Aiaa, T. Tetrahydrocannabinol for neuropsychiatric symptoms in dementia a randomized controlled trial. G. Am. Acad. Neurol., 2015, 84(23), 2338-2346.
[http://dx.doi.org/10.1212/WNL.0000000000001675] [PMID: 25972490]

Bilginer, S.; Anil, B.; Koca, M.; Demir, Y.; Gülçin, I. novel mannich bases with strong carbonic anhydrases and acetylcholinesterase inhibition effects: 3-(Aminomethyl)-6-{3-[4-(Trifluoromethyl)Phenyl]Acryloyl}-2(3H)-. Benzoxazolones. Turk. J. Chem., 2021, 45(3), 805-818.
[http://dx.doi.org/10.3906/kim-2101-25] [PMID: 34385868]

Oboh, G.; Adedayo, B.C.; Adetola, M.B.; Oyeleye, I.S.; Ogunsuyi, O.B. Characterization and neuroprotective properties of alkaloid extract of Vernonia amygdalina Delile in experimental models of Alzheimer’s disease. Drug Chem. Toxicol., 2022, 45(2), 731-740.
[http://dx.doi.org/10.1080/01480545.2020.1773845] [PMID: 32543989]

Himalian, R.; Singh, S.K.; Singh, M.P. Ameliorative Role of Nutraceuticals on Neurodegenerative Diseases Using the Drosophila Melanogaster as a Discovery Model to Define Bioefficacy. J. Am. Nutr. Assoc., 2022, 14(5), 511-539.
[http://dx.doi.org/10.1080/07315724.2021.1904305] [PMID: 34125661]

Sadhukhan, P.; Saha, S.; Dutta, S.; Mahalanobish, S.; Sil, P.C. Nutraceuticals: An emerging therapeutic approach against the pathogenesis of Alzheimer’s Disease; Elsevier Ltd., 2018, p. 129.
[http://dx.doi.org/10.1016/j.phrs.2017.11.028]

Mori, T.; Koyama, N.; Tan, J.; Segawa, T.; Maeda, M.; Town, T. Combined treatment with the phenolics (−)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice. J. Biol. Chem., 2019, 294(8), 2714-5444.
[http://dx.doi.org/10.1074/jbc.RA118.004280] [PMID: 30563837]

Pandareesh, M.D.; Chauhan, V.; Chauhan, A. Walnut Supplementation in the Diet Reduces Oxidative Damage and Improves Antioxidant Status in Transgenic Mouse Model of Alzheimer’s Disease. J. Alzheimers Dis., 2018, 64(4), 1295-1305.
[http://dx.doi.org/10.3233/JAD-180361] [PMID: 30040727]

Rainey-Smith, S.R.; Brown, B.M.; Sohrabi, H.R.; Shah, T.; Goozee, K.G.; Gupta, V.B.; Martins, R.N. Curcumin and cognition: A randomised, placebo-controlled, double-blind study of community-dwelling older adults. Br. J. Nutr., 2016, 115(12), 2106-2113.
[http://dx.doi.org/10.1017/S0007114516001203] [PMID: 27102361]

Malhotra, A.; Bath, S.; Elbarbry, F. An organ system approach to explore the antioxidative, anti-inflammatory and cytoprotective actions of resveratrol. Oxid. Med. Cell. Longev., 2015, 2015, 1-15.
[http://dx.doi.org/10.1155/2015/803971] [PMID: 26180596]

Jardim, F.R.; de Rossi, F.T.; Nascimento, M.X.; da Silva Barros, R.G.; Borges, P.A.; Prescilio, I.C.; de Oliveira, M.R. Resveratrol and brain mitochondria: A review. Mol. Neurobiol., 2018, 55(3), 2085-2101.
[http://dx.doi.org/10.1007/s12035-017-0448-z] [PMID: 28283884]

Wichur, T.; Pasieka, A. Godyń J.; Panek, D.; Góral, I.; Latacz, G.; Honkisz-Orzechowska, E.; Bucki, A.; Siwek, A.; Głuch-Lutwin, M.; Knez, D.; Brazzolotto, X.; Gobec, S.; Kołaczkowski, M.; Sabate, R.; Malawska, B.; Więckowska, A. Discovery of 1-(phenylsulfonyl)-1H-indole-based multifunctional ligands targeting cholinesterases and 5-HT6 receptor with anti-aggregation properties against amyloid-beta and tau. Eur. J. Med. Chem., 2021, 225, 113783.
[http://dx.doi.org/10.1016/j.ejmech.2021.113783] [PMID: 34461507]

Moussa, C.; Hebron, M.; Huang, X.; Ahn, J.; Rissman, R.A.; Aisen, P.S.; Turner, R.S. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s Disease. J. Neuroinflammation, 2017, 14(1), 1-10.
[http://dx.doi.org/10.1186/s12974-016-0779-0] [PMID: 28086917]

Schweiger, S.; Matthes, F.; Posey, K.; Kickstein, E.; Weber, S.; Hettich, M.M.; Pfurtscheller, S.; Ehninger, D.; Schneider, R.; Krauß, S. Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex. Sci. Rep., 2017, 7(1), 13753.
[http://dx.doi.org/10.1038/s41598-017-12974-4] [PMID: 29062069]

Corpas, R.; Griñán-Ferré, C.; Rodríguez-Farré, E.; Pallàs, M.; Sanfeliu, C. Resveratrol induces brain resilience against alzheimer neurodegeneration through proteostasis enhancement. Mol. Neurobiol., 2019, 56(2), 1502-1516.
[http://dx.doi.org/10.1007/s12035-018-1157-y] [PMID: 29948950]

Turner, R.S.; Thomas, R.G.; Craft, S.; van Dyck, C.H.; Mintzer, J.; Reynolds, B.A.; Brewer, J.B.; Rissman, R.A.; Raman, R.; Aisen, P.S. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology, 2015, 85(16), 1383-1391.
[http://dx.doi.org/10.1212/WNL.0000000000002035] [PMID: 26362286]

Wu, L.; Sun, D.; He, Y. Coffee intake and the incident risk of cognitive disorders: A dose–response meta-analysis of nine prospective cohort studies. Clin. Nutr., 2017, 36(3), 730-736.
[http://dx.doi.org/10.1016/j.clnu.2016.05.015] [PMID: 27288328]

Santos, G.L.; Hartmann, S.; Zimmermann, W.H.; Ridley, A.; Lutz, S. Inhibition of Rho-associated kinases suppresses cardiac myofibroblast function in engineered connective and heart muscle tissues. J. Mol. Cell. Cardiol., 2019, 134(134), 13-28.
[http://dx.doi.org/10.1016/j.yjmcc.2019.06.015] [PMID: 31233754]

Kim, Y.S.; Kwak, S.M.; Myung, S.K. Caffeine intake from coffee or tea and cognitive disorders: A meta-analysis of observational studies. Neuroepidemiology, 2015, 44(1), 51-63.
[http://dx.doi.org/10.1159/000371710] [PMID: 25721193]

Reidel, W.; Hogervorst, E.; Leboux, R.; Verhey, F.; van Praag, H.; Jolles, J. Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology, 1995, 122(2), 158-168.
[http://dx.doi.org/10.1007/BF02246090] [PMID: 8848531]

Cascella, M.; Bimonte, S.; Muzio, M.R.; Schiavone, V.; Cuomo, A. The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer’s disease: An overview of pre-clinical studies and translational perspectives in clinical practice. Infect. Agent. Cancer, 2017, 12(1), 36.
[http://dx.doi.org/10.1186/s13027-017-0145-6] [PMID: 28642806]

Jin, G.; Bai, D.; Yin, S.; Yang, Z.; Zou, D.; Zhang, Z.; Li, X.; Sun, Y.; Zhu, Q. Silibinin rescues learning and memory deficits by attenuating microglia activation and preventing neuroinflammatory reactions in SAMP8 mice. Neurosci. Lett., 2016, 629, 256-261.
[http://dx.doi.org/10.1016/j.neulet.2016.06.008] [PMID: 27276653]

Hostetler, G.L.; Ralston, R.A.; Schwartz, S.J. Flavones  Food sources; Bioavailability, 2017, pp. 423-435.

Wu, L.; Tong, T.; Wan, S.; Yan, T.; Ren, F.; Bi, K.; Jia, Y. Protective effects of puerarin against Aβ 1-42-induced learning and memory impairments in mice. Planta Med., 2016, 83(03/04), 224-231.
[http://dx.doi.org/10.1055/s-0042-111521] [PMID: 27420352]

Dommels, Y. Effects of N-6 and n-3 polyunsaturated fatty acids on colorectal carcinogenesis. 2017, 9(1), 1-9.

Lo Verme, J.; Fu, J.; Astarita, G.; La Rana, G.; Russo, R.; Calignano, A.; Piomelli, D. The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol., 2005, 67(1), 15-19.
[http://dx.doi.org/10.1124/mol.104.006353] [PMID: 15465922]

Beggiato, S.; Tomasini, M.C.; Ferraro, L. Palmitoylethanolamide (PEA) as a potential therapeutic agent in alzheimer’s disease. Front. Pharmacol., 2019, 10(July), 821.
[http://dx.doi.org/10.3389/fphar.2019.00821] [PMID: 31396087]

Andrieu, S.; Guyonnet, S.; Coley, N.; Cantet, C.; Bonnefoy, M.; Bordes, S.; Bories, L.; Cufi, M.N.; Dantoine, T.; Dartigues, J.F.; Desclaux, F.; Gabelle, A.; Gasnier, Y.; Pesce, A.; Sudres, K.; Touchon, J.; Robert, P.; Rouaud, O.; Legrand, P.; Payoux, P.; Caubere, J.P.; Weiner, M.; Carrié, I.; Ousset, P.J.; Vellas, B.; Vellas, B.; Guyonnet, S.; Carrié, I.; Brigitte, L.; Faisant, C.; Lala, F.; Delrieu, J.; Villars, H.; Combrouze, E.; Badufle, C.; Zueras, A.; Andrieu, S.; Cantet, C.; Morin, C.; Van Kan, G.A.; Dupuy, C.; Rolland, Y.; Caillaud, C.; Ousset, P-J.; Fougère, B.; Willis, S.; Belleville, S.; Gilbert, B.; Fontaine, F.; Dartigues, J-F.; Marcet, I.; Delva, F.; Foubert, A.; Cerda, S.; Noëlle-Cuffi, M.; Costes, C.; Rouaud, O.; Manckoundia, P.; Quipourt, V.; Marilier, S.; Franon, E.; Bories, L.; Pader, M-L.; Basset, M-F.; Lapoujade, B.; Faure, V.; Li, M.; Tong, Y.; Malick-Loiseau, C.; Cazaban-Campistron, E.; Desclaux, F.; Blatge, C.; Dantoine, T.; Laubarie-Mouret, C.; Saulnier, I.; Clément, J-P.; Picat, M-A.; Bernard-Bourzeix, L.; Willebois, S.; Désormais, I.; Cardinaud, N.; Bonnefoy, M.; Livet, P.; Rebaudet, P.; Gédéon, C.; Burdet, C.; Terracol, F.; Pesce, A.; Roth, S.; Chaillou, S.; Louchart, S.; Sudres, K.; Lebrun, N.; Barro-Belaygues, N.; Touchon, J.; Bennys, K.; Gabelle, A.; Romano, A.; Touati, L.; Marelli, C.; Pays, C.; Robert, P.; Le Duff, F.; Gervais, C.; Gonfrier, S.; Gasnier, Y.; Bordes, S.; Begorre, D.; Carpuat, C.; Khales, K.; Lefebvre, J-F.; El Idrissi, S.M.; Skolil, P.; Salles, J-P.; Dufouil, C.; Lehéricy, S.; Chupin, M.; Mangin, J-F.; Bouhayia, A.; Allard, M.; Ricolfi, F.; Dubois, D.; Paule, M.; Martel, B.; Cotton, F.; Bonafé, A.; Chanalet, S.; Hugon, F.; Bonneville, F.; Cognard, C.; Chollet, F.; Payoux, P.; Voisin, T.; Peiffer, S.; Hitzel, A.; Allard, M.; Zanca, M.; Monteil, J.; Darcourt, J.; Molinier, L.; Derumeaux, H.; Costa, N.; Vincent, C.; Perret, B.; Vinel, C.; Olivier-Abbal, P. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): A randomised, placebo-controlled trial. Lancet Neurol., 2017, 16(5), 377-389.
[http://dx.doi.org/10.1016/S1474-4422(17)30040-6] [PMID: 28359749]

Im, D.S. Pro-resolving effect of ginsenosides as an anti-inflammatory mechanism of Panax ginseng. Biomolecules, 2020, 10(3), 444.
[http://dx.doi.org/10.3390/biom10030444] [PMID: 32183094]

Du, Y.; Fu, M.; Wang, Y.T.; Dong, Z. Neuroprotective effects of ginsenoside rf on amyloid-β-induced neurotoxicity in vitro and in vivo. J. Alzheimers Dis., 2018, 64(1), 309-322.
[http://dx.doi.org/10.3233/JAD-180251] [PMID: 29865080]

Sachdeva, A.K.; Chopra, K. Lycopene abrogates Aβ(1–42)-mediated neuroinflammatory cascade in an experimental model of Alzheimer’s Disease. J. Nutr. Biochem., 2015, 26(7), 736-744.
[http://dx.doi.org/10.1016/j.jnutbio.2015.01.012] [PMID: 25869595]

von Arnim, C.A.F.; Herbolsheimer, F.; Nikolaus, T.; Peter, R.; Biesalski, H.K.; Ludolph, A.C.; Riepe, M.; Nagel, G. Dietary antioxidants and dementia in a population-based case-control study among older people in South Germany. J. Alzheimers Dis., 2012, 31(4), 717-724.
[http://dx.doi.org/10.3233/JAD-2012-120634] [PMID: 22710913]

Atkinson, F. S.; Villar, A.; Mul, A.; Zangara, A.; Risco, E.; Smidt, C. R.; Hontecillas, R.; Leber, A.; Bassaganya-riera, J. Responses in Healthy Adults. 2006, 1.

Khorasani, A.; Abbasnejad, M.; Esmaeili-Mahani, S. Phytohormone abscisic acid ameliorates cognitive impairments in streptozotocin-induced rat model of Alzheimer’s Disease through PPARβ/δ and PKA signaling. Int. J. Neurosci., 2019, 129(11), 1053-1065.
[http://dx.doi.org/10.1080/00207454.2019.1634067] [PMID: 31215291]

Sánchez-Sarasúa, S.; Moustafa, S.; García-Avilés, Á.; López-Climent, M.F.; Gómez-Cadenas, A.; Olucha-Bordonau, F.E.; Sánchez-Pérez, A.M. The effect of abscisic acid chronic treatment on neuroinflammatory markers and memory in a rat model of high-fat diet induced neuroinflammation. Nutr. Metab., 2016, 13(1), 73.
[http://dx.doi.org/10.1186/s12986-016-0137-3] [PMID: 27795733]

Ribes-Navarro, A.; Atef, M.; Sánchez-Sarasúa, S.; Beltrán-Bretones, M.T.; Olucha-Bordonau, F.; Sánchez-Pérez, A.M. Abscisic acid supplementation rescues high fat diet-induced alterations in hippocampal inflammation and irss expression. Mol. Neurobiol., 2019, 56(1), 454-464.
[http://dx.doi.org/10.1007/s12035-018-1091-z] [PMID: 29721854]

Espinosa-Fernández, V.; Mañas-Ojeda, A.; Pacheco-Herrero, M.; Castro-Salazar, E.; Ros-Bernal, F.; Sánchez-Pérez, A.M. Early intervention with ABA prevents neuroinflammation and memory impairment in a triple transgenic mice model of Alzheimer’s Disease. Behav. Brain Res., 2019, 374(June), 112106.
[http://dx.doi.org/10.1016/j.bbr.2019.112106] [PMID: 31356828]

Kan, L.; Smith, A.; Chen, M.; Ledford, B.T.; Fan, H. Rho-associated kinase inhibitor (Y-27632); Attenuates Doxorubicin-Induced Apoptosis of Human Cardiac Stem Cells, 2015, pp. 1-21.
[http://dx.doi.org/10.1371/journal.pone.0144513]

Heo, J.H.; Lee, S.T.; Chu, K.; Oh, M.J.; Park, H.J.; Shim, J.Y.; Kim, M. Heat-processed ginseng enhances the cognitive function in patients with moderately severe Alzheimer’s disease. Nutr. Neurosci., 2012, 15(6), 278-282.
[http://dx.doi.org/10.1179/1476830512Y.0000000027] [PMID: 22780999]

Zou, K.; Abdullah, M.; Michikawa, M. Current biomarkers for Alzheimer’s disease: From CSF to Blood. J. Pers. Med., 2020, 10(3), 85.
[http://dx.doi.org/10.3390/jpm10030085] [PMID: 32806668]

Jain, S.; Chauhan, N.; Sharma, S.; Reddy, K.R.; Sadhu, V.; Kulkarni, R.V. The link between anxiety and Alzheimer’s disease: Critical facts; INC, 2020.
[http://dx.doi.org/10.1016/B978-0-12-817923-9.00012-2]

Watt, G.; Karl, T. In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease. Front. Pharmacol., 2017, 8(FEB), 20.
[http://dx.doi.org/10.3389/fphar.2017.00020] [PMID: 28217094]

Patel, S.; Shukla, J.; Jain, S.; Paliwal, V.; Tripathi, N.; Paliwal, S.; Sharma, S. Repositioning of tubocurarine as analgesic and anti-inflammatory agent: Exploring beyond myorelaxant activity. Biochem. Pharmacol., 2022, 205(May), 115248.
[http://dx.doi.org/10.1016/j.bcp.2022.115248] [PMID: 36113566]

Sharma, M.; Mittal, A.; Singh, A.; Jainarayanan, A.K.; Sharma, S.; Paliwal, S. Pharmacophore-driven identification of N-methyl-D-receptor antagonists as potent neuroprotective agents validated using in vivo studies. Biol. Methods Protoc., 2020, 5(1), bpaa013.
[http://dx.doi.org/10.1093/biomethods/bpaa013] [PMID: 32913897]

Outen, J.D.; Burhanullah, M.H.; Vandrey, R.; Amjad, H.; Harper, D.G.; Patrick, R.E.; May, R.L.; Agronin, M.E.; Forester, B.P.; Rosenberg, P.B. Cannabinoids for agitation in Alzheimer’s Disease. Am. J. Geriatr. Psychiatry, 2021, 29(12), 1253-1263.
[http://dx.doi.org/10.1016/j.jagp.2021.01.015] [PMID: 33573996]

Jain, S.; Chauhan, N.; Bhardwaj, A.; Yadaw, G.; Singh, M.K.; Mishra, A. QSAR Modeling of α-Ketooxazole Motif Analogues as Potent Anti-Alzheimer Agents. YMER Digital, 2022, 21(5), 624-640.
[http://dx.doi.org/10.37896/YMER21.05/71]

Bilkei-Gorzo, A.; Racz, I.; Valverde, O.; Otto, M.; Michel, K.; Sarstre, M.; Zimmer, A. Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors. Proc. Natl. Acad. Sci., 2005, 102(43), 15670-15675.
[http://dx.doi.org/10.1073/pnas.0504640102] [PMID: 16221768]

Ramírez, B.G.; Blázquez, C.; Gómez del Pulgar, T.; Guzmán, M.; de Ceballos, M.L. Prevention of Alzheimer’s Disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J. Neurosci., 2005, 25(8), 1904-1913.
[http://dx.doi.org/10.1523/JNEUROSCI.4540-04.2005] [PMID: 15728830]

Gorey, C.; Kuhns, L.; Smaragdi, E.; Kroon, E.; Cousijn, J. Age-related differences in the impact of cannabis use on the brain and cognition: A systematic review. Eur. Arch. Psychiatry Clin. Neurosci., 2019, 269(1), 37-58.
[http://dx.doi.org/10.1007/s00406-019-00981-7] [PMID: 30680487]

Rouyer, O.; Geny, B. Evolocumab in hyperlipidemia. N. Engl. J. Med., 2014, 371(9), 876-878.
[http://dx.doi.org/10.1056/NEJMc1408237]

Patel, S.; Gururani, R.; Jain, S.; Tripathi, N.; Paliwal, S.; Paliwal, S.; Paliwal, S.; Sharma, S. Repurposing of digoxin in pain and inflammation: An evidence‐based study. Drug Dev. Res., 2022, 83(5), 1097-1110.
[http://dx.doi.org/10.1002/ddr.21935] [PMID: 35315525]

Cassano, T.; Calcagnini, S.; Pace, L.; De Marco, F.; Romano, A.; Gaetani, S. Cannabinoid receptor 2 signaling in neurodegenerative disorders: From pathogenesis to a promising therapeutic target. Front. Neurosci., 2017, 11(FEB), 30.
[http://dx.doi.org/10.3389/fnins.2017.00030] [PMID: 28210207]

Kendall, D.A.; Yudowski, G.A. Cannabinoid receptors in the central nervous system: Their signaling and roles in disease. Front. Cell. Neurosci., 2017, 10, 294.
[http://dx.doi.org/10.3389/fncel.2016.00294] [PMID: 28101004]

Tolón, R.M.; Núñez, E.; Pazos, M.R.; Benito, C.; Castillo, A.I.; Martínez-Orgado, J.A.; Romero, J. The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res., 2009, 1283, 148-154.
[http://dx.doi.org/10.1016/j.brainres.2009.05.098] [PMID: 19505450]

Solas, M.; Francis, P.T.; Franco, R.; Ramirez, M.J. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer’s disease patients. Neurobiol. Aging, 2013, 34(3), 805-808.
[http://dx.doi.org/10.1016/j.neurobiolaging.2012.06.005] [PMID: 22763024]

Tak, K.; Sharma, P.; Sharma, R.; Dave, V.; Jain, S.; Sharma, S. One-pot hydrothermal green synthesis of Polygala tenuifolia mediated graphene quantum dots for acetylcholine esterase inhibitory activity. J. Drug Deliv. Sci. Technol., 2022, 73, 103486.
[http://dx.doi.org/10.1016/j.jddst.2022.103486]

Aso, E.; Juvés, S.; Maldonado, R.; Ferrer, I. CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. J. Alzheimers Dis., 2013, 35(4), 847-858.
[http://dx.doi.org/10.3233/JAD-130137] [PMID: 23515018]

Amandine, E.B.; Yannick, M. Potential therapeutical contributions of the endocannabinoid system towards aging and Alzheimer’s Disease. Aging Dis., 2015, 6(5), 400-405.
[http://dx.doi.org/10.14336/AD.2015.0617] [PMID: 26425394]

Cassano, T.; Villani, R.; Pace, L.; Carbone, A.; Bukke, V.N.; Orkisz, S.; Avolio, C.; Serviddio, G. From Cannabis sativa to Cannabidiol: Promising therapeutic candidate for the treatment of neurodegenerative diseases. Front. Pharmacol., 2020, 11, 124.
[http://dx.doi.org/10.3389/fphar.2020.00124] [PMID: 32210795]

Pihlaja, R.; Takkinen, J.; Eskola, O.; Vasara, J.; López-Picón, F.R.; Haaparanta-Solin, M.; Rinne, J.O. Monoacylglycerol lipase inhibitor JZL184 reduces neuroinflammatory response in APdE9 mice and in adult mouse glial cells. J. Neuroinflammation, 2015, 12(1), 81.
[http://dx.doi.org/10.1186/s12974-015-0305-9] [PMID: 25927213]

Woelfl, T.; Rohleder, C.; Mueller, J.K.; Lange, B.; Reuter, A.; Schmidt, A.M.; Koethe, D.; Hellmich, M.; Leweke, F.M. Effects of cannabidiol and delta-9-tetrahydrocannabinol on emotion, cognition, and attention: A double-blind, placebo-controlled, randomized experimental trial in healthy volunteers. Front. Psychiatry, 2020, 11(11), 576877.
[http://dx.doi.org/10.3389/fpsyt.2020.576877] [PMID: 33304282]

Tak, K.; Sharma, R.; Dave, V.; Jain, S.; Sharma, S. Clitoria ternatea Mediated Synthesis of Graphene Quantum Dots for the Treatment of Alzheimer’s Disease. ACS Chem. Neurosci., 2020, 11(22), 3741-3748.
[http://dx.doi.org/10.1021/acschemneuro.0c00273] [PMID: 33119989]

Pertwee, R.G. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9 -tetrahydrocannabinol, cannabidiol and Δ 9 -tetrahydrocannabivarin. Br. J. Pharmacol., 2008, 153(2), 199-215.
[http://dx.doi.org/10.1038/sj.bjp.0707442] [PMID: 17828291]

Chung, H.; Fierro, A.; Pessoa-Mahana, C.D. Cannabidiol binding and negative allosteric modulation at the cannabinoid type 1 receptor in the presence of delta-9-tetrahydrocannabinol: An in silico study. PLoS One, 2019, 14(7), e0220025.
[http://dx.doi.org/10.1371/journal.pone.0220025] [PMID: 31335889]

Laprairie, R.B.; Bagher, A.M.; Kelly, M.E.M.; Denovan-Wright, E.M. Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor. Br. J. Pharmacol., 2015, 172(20), 4790-4805.
[http://dx.doi.org/10.1111/bph.13250] [PMID: 26218440]

Tham, M.; Yilmaz, O.; Alaverdashvili, M.; Kelly, M.E.M.; Denovan-Wright, E.M.; Laprairie, R.B. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. Br. J. Pharmacol., 2019, 176(10), 1455-1469.
[http://dx.doi.org/10.1111/bph.14440] [PMID: 29981240]

Scuderi, C.; Steardo, L.; Esposito, G. Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARγ involvement. Phytother. Res., 2014, 28(7), 1007-1013.
[http://dx.doi.org/10.1002/ptr.5095] [PMID: 24288245]

Janefjord, E.; Mååg, J.L.V.; Harvey, B.S.; Smid, S.D. Cannabinoid effects on β amyloid fibril and aggregate formation, neuronal and microglial-activated neurotoxicity in vitro. Cell. Mol. Neurobiol., 2014, 34(1), 31-42.
[http://dx.doi.org/10.1007/s10571-013-9984-x] [PMID: 24030360]

Cheng, D.; Spiro, A.S.; Jenner, A.M.; Garner, B.; Karl, T. Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer’s disease transgenic mice. J. Alzheimers Dis., 2014, 42(4), 1383-1396.
[http://dx.doi.org/10.3233/JAD-140921] [PMID: 25024347]

Thompson, K.J.; Tobin, A.B. Crosstalk between the M1 muscarinic acetylcholine receptor and the endocannabinoid system: A relevance for Alzheimer’s disease? Cell. Signal., 2020, 70(1), 109545.
[http://dx.doi.org/10.1016/j.cellsig.2020.109545] [PMID: 31978506]